Alcoholism, Drug Abuse |
No. |
|
Metabolic Diseases |
No. |
 |
CDT in Serum |
21000 |
|
 |
5-Aminolevulinic Acid/Porphobilinogen in Urine |
17200 |
 |
CDT in Serum - On-Line Analysis |
21100 |
|
 |
Homocysteine in Plasma |
23000 |
 |
CDT in Serum - Automated On-Line Analysis |
21200 |
|
 |
Hydroxyproline in Urine |
16000 |
 |
Basic Drugs in Urine - On-Line Analysis |
60000 |
|
 |
Phe, Tyr, Trp in Whole Blood, Plasma,Filterspots |
10000 |
 |
Pharmaceuticals in Plasma - On-Line Analysis
with TOX.I.S.™ |
60200 |
|
 |
Porphyrins Dfferentiated in Urine |
17000 |
 |
Pharmaceuticals in Urine - On-Line Analysis
with TOX.I.S.™ |
60100 |
|
 |
Total Porhyrins in Urine |
17100 |
| |
|
|
|
|
|
Biogenic Amines |
|
Oxidative Stress |
|
 |
Catecholamines in Plasma |
1000 |
|
 |
Coenzyme Q10 in Whole Blood/Plasma/Serum |
31000 |
 |
Catecholamines in Urine |
2000 |
|
 |
Malondialdehyde in Plasma/Serum |
32000 |
 |
Catecholamines in Urine, APS3000 |
2400 |
|
 |
Vitamin C in Plasma |
28000 |
 |
Catecholamines in Urine, Gilson®Aspec™ |
2200 |
|
|
|
|
 |
Catecholamines in Urine-On-Line Analysis |
2100 |
|
|
|
|
 |
Metanephrines in Urine |
4000 |
|
Vitamin Status |
|
 |
Metanephrines in Urine_APS 3000 |
4300 |
|
 |
Vitamins A and E in Plasma |
22000 |
 |
Metanephrines in Urine|
Gilson® Aspec™ |
4100 |
|
 |
Vitamin B1 in Whole Blood |
24000 |
 |
Serotonin in Plasma |
6000 |
|
 |
Vitamin B2 in Whole Blood |
25000 |
 |
Serotonin in Urine |
7000 |
|
 |
Vitamin B6 in Plasma/Whole Blood |
26000 |
 |
VMA, HVA, 5-HIAA in Urine |
3000 |
|
 |
Vitamin B1, B2, B6 in Whole Blood/Plasma (Combikit) |
27000 |
 |
VMA, HVA, 5-HIAA in Urine (APS3000) |
3300 |
|
 |
25-OH-Vitamin D2/D3 in Plasma/Serum |
35000 |
 |
VMA, HVA, 5-HIAA in Urine| Gilson® Aspec™ |
3100 |
|
 |
25-OH-Vitamin D2/D3 in Plasma/Serum with UPLC® |
35100 |
| |
|
|
|
|
|
Diabetes Hemoglobin Testing |
|
|
|
|
|
 |
HbA1c in Whole Blood with Diamat™ |
11000 |
|
|
|
|
 |
HbA1c in Whole Blood with Variant™ |
11100 |
|
|
|
|
 |
Hb Variants, ß-Thalass.-Scr., Whole Blood |
13100 |
|
|
|
|
| |
|
|
|
|
|
|
| |
|